Since the CD38-targeted formulation improved efficacy over the nontargeted nanoparticles, these results demonstrate their potential as a new treatment option over the current standard treatment Doxil in multiple myeloma cases that overexpress CD38. The gene discussed is CD38; the disease is plasma cell myeloma.